Sarepta Therapeutics (SRPT) Posts Slightly Smaller Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Wall Street climbs as Broadcom and other chipmakers rally
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Dara Khosrowshahi steps down from Grab Holdings board
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Wall Street climbs as Broadcom and other chipmakers rally
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments
May 5, 2016 7:01 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc.(NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months ended March 31, 2016, and provided an update of recent corporate developments.
The Peripheral and Central Nervous System Advisory Committee met last week to review eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping, and we await our May 26 PDUFA date, said Edward Kaye, M.D., Sareptas interim chief executive officer and chief medical officer. Following the FDAs decision, we plan to provide a clinical and corporate update.
... More